The role of mast cells in the pathogenesis of chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease (COPD) is one of major causes of chronic noncommunicable diseases and mortality worldwide. The roles of macrophages, T-lymphocytes, neutrophils, and other cells in the development of chronic inflammation in this disease are well studied, but more and more researchers have focused on mast cells (MC) in recent years.

The aim of this work is to summarize the data of experimental and clinical studies on the possible role of MCs in the pathogenesis of COPD. To this end, the review analyzed data on the relationship between MCs and respiratory function parameters in COPD, as well as the distribution of MCs subpopulations in different parts of the respiratory tract. The involvement of proteases (chymase and tryptase) in the development of inflammatory and fibrotic changes in COPD is discussed. The review presents research findings that indicate the possible involvement of chymase in pulmonary artery remodeling, increased secretion of mucins, and slowing down the airway epithelial repair. The role of MC tryptase in the development of fibrotic changes in the lungs and airways in COPD is also highlighted. A separate section of the review is devoted to chemokines that promote MC migration and their specific receptor. Chemokines play a special role in the development of inflammation in COPD.

Conclusion. The available data suggest that MCs play a major role in the pathogenesis of COPD. Because of the inconsistency of some results, further clinical studies in larger cohorts of patients are needed.

1. World Health Organization. The top 10 causes of death. Fact sheets. Available at: https://www.who.int/ru/news-room/fact-sheets/detail/the-top-10-causes-of-death [Accessed: January 31, 2020].

2. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. 2022 Report. Available at: https://goldcopd.org/wp-content/uploads/2021/12/GOLD-REPORT-2022-v1.1-22Nov2021_WMV.pdf [Accessed: January 31, 2021].

3. Budnevsky A.V., Isaeva Ya.V., Malysh E.Yu., Kozhevnikova S.A. [Pulmonary rehabilitation as an effective method for optimizing therapeutic and preventive measures in patients with chronic obstructive pulmonary disease concurrent with metabolic syndrome]. Terapevticheskiy arkhiv. 2016; 88 (8): 25-29. https://doi.org/10.17116/terarkh201688825-29 (in Russian).

4. Kozhevnikova S.A., Budnevsky A.V., Ovsyannikov E.S., Belov V.N. [Particularity of the clinical course and quality of life of patients with chronic obstructive pulmonary disease on the background of the metabolic syndrome]. Meditsinkiy vestnik Severnogo Kavkaza. 2017; 12 (1): 20-23. https://doi.org/10.14300/mnnc.2017.12006 (in Russian).

5. Provotorov V.M., Budnevsky A.V., Semenkova G.G., Shishkina E.S. [Proinflammatory cytokines in combination of coronary heart disease and chronic obstructive pulmonary disease]. Klinicheskaya meditsina. 2015; 93 (2): 5-9. Available at: https://cyberleninka.ru/article/n/provospalitelnye-tsitokiny-pri-sochetanii-ishemicheskoy-bolezni-serdtsa-i-hronicheskoy-obstruktivnoy-bolezni-legkih/viewer (in Russian).

6. Valipour A., Aisanov Z., Avdeev S. et al. Recommendations for COPD management in Central and Eastern Europe. Expert. Rev. Respir. Med. 2022; 16 (2): 221-234. https://doi.org/10.1080/17476348.2021.2023498.

7. Chernyak B.A., Petrovskiy F.I. [Inflammation in COPD: clinical significance and possibilities of pharmacotherapeutic control]. Atmosfera. Pul’monologiya i allergologiya. 2008; (1): 23-28. Available at: https://cyberleninka.ru/article/n/vospalenie-pri-hobl-klinicheskoeznachenie-i-vozmozhnosti-farmakoterapevticheskogo-kontrolya/viewer (in Russian).

8. Cruse G., Bradding P. Mast cells in airway diseases and interstitial lung disease. Eur. J. Pharmacol. 2016; 778: 125-138. https://doi.org/10.1016/j.ejphar.2015.04.046.

9. Wen Y., Reid D.W., Zhang D. et al. Assessment of airway inflammation using sputum, BAL, and endobronchial biopsies in current and ex-smokers with established COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2010; 5: 327-334. https://doi.org/10.2147/COPD.S11343.

10. Soltani A., Ewe Y.P., Lim Z.S. et al. Mast cells in COPD airways: relationship to bronchodilator responsiveness and angiogenesis. Eur. Respir. J. 2012; 39 (6): 1361-1367. https://doi.org/10.1183/09031936.00084411.

11. Kuzubova N.A., Lebedeva E.S., Titova O.N. et al. Role of mast cells in bronchial contraction in nonallergic obstructive lung pathology. J. Smooth. Muscle Res. 2017; 53: 90-99. https://doi.org/10.1540/jsmr.53.90.

12. Nussbaumer-Ochsner Y., Stolk J., Ferraz da Silva L.F. et al. Association of lung inflammatory cells with small airways function and exhaled breath markers in smokers - is there a specific role for mast cells? PLoS One. 2015; 10 (6): e0129426. https://doi.org/10.1371/journal.pone.0129426.

13. Andersson C.K., Mori M., Bjermer L. et al. Alterations in lung mast cell populations in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2010; 181 (3): 206-217. https://doi.org/10.1164/rccm.200906-0932OC.

14. Atyakshin D.A., Bukhvalov I.B., Timann M. [Mast cell proteases in specific tissular microenvironment formation: pathogenetic and diagnostical aspects]. Terapiya. 2018; 6 (24): 128-140. https://doi.org/10.18565/therapy.2018.6.128-140 (in Russian).

15. Ammendola M., Sacco R., Sammarco G. et al. Mast cell-targeted strategies in cancer therapy. Transfus. Med. Hemother. 2016; 43 (2):109-113. https://doi.org/10.1159/000444942.

16. Caughey G.H. Mast cell proteases as pharmacological targets. Eur. J. Pharmacol. 2016; 778: 44-55. https://doi.org/10.1016/j.ejphar.2015.04.045.

17. Dell’Italia L.J., Collawn J.F., Ferrario C.M. Multifunctional role of chymase in acute and chronic tissue injury and remodeling. Circ. Res. 2018; 122 (2): 319-336. https://doi.org/10.1161/CIRCRESAHA.117.310978.

18. Maryanoff B.E., de Garavilla L., Greco M.N. et al. Dual inhibition of cathepsin G and chymase is effective in animal models of pulmonary inflammation. Am. J. Respir. Crit. Care Med. 2010; 181 (3): 247-253. https://doi.org/10.1164/rccm.200904-0627OC.

19. Wang T., Han S.X., Zhang S.F. et al. Role of chymase in cigarette smoke-induced pulmonary artery remodeling and pulmonary hypertension in hamsters. Respir. Res. 2010; 11 (1): 36. https://doi.org/10.1186/14659921-11-36.

20. Kosanovic D., Dahal B.K., Peters D.M. et al. Histological characterization of mast cell chymase in patients with pulmonary hypertension and chronic obstructive pulmonary disease. Pulm. Circ. 2014; 4 (1): 128-136. https://doi.org/10.1086/675642.

21. He S.H., Zheng J. Stimulation of mucin secretion from human bronchial epithelial cells by mast cell chymase. Acta Pharmacol. Sin. 2004; 25 (6): 827-832. Available at: https://pubmed.ncbi.nlm.nih.gov/15169640

22. Gordins P., Purkiss J.R., Lackie P.M. et al. The inhibition of epithelial repair by mast cell chymase. J. Allergy Clin. Immunol. 2005; 115 (2, Suppl.): S206. https://doi.org/10.1016/j.jaci.2004.12.837.

23. Zhou X., Wei T., Cox C.W. et al. Mast cell chymase impairs bronchial epithelium integrity by degrading cell junction molecules of epithelial cells. Allergy. 2019; 74 (7): 1266-1276. https://doi.org/10.1111/all.13666.

24. Gosman M.M., Postma D.S., Vonk J.M. et al. Association of mast cells with lung function in chronic obstructive pulmonary disease. Respir. Res. 2008; 9 (1): 64. https://doi.org/10.1186/1465-9921-9-64.

25. Zhang X., Zheng H., Ma W. et al. Tryptase enzyme activity is correlated with severity of chronic obstructive pulmonary disease. Tohoku J. Exp. Med. 2011; 224 (3): 179-187. https://doi.org/10.1620/tjem.224.179.

26. Beckett E.L., Stevens R.L., Jarnicki A.G. et al. A new short-term mouse model of chronic obstructive pulmonary disease identifies a role for mast cell tryptase in pathogenesis. J. Allergy Clin. Immunol. 2013; 131 (3): 752-762. https://doi.org/10.1016/j.jaci.2012.11.053.

27. Brightling C.E., Ammit A.J., Kaur D. et al. The CXCL10/CXCR3 axis mediates human lung mast cell migration to asthmatic airway smooth muscle. Am. J. Respir. Crit. Care Med. 2005; 171 (10): 1103- 1108. https://doi.org/10.1164/rccm.200409-1220OC.

28. Wang Y., Zhou Q., Dong L. et al. The effects of CXCL10 polymorphisms on COPD susceptibility. Mol. Genet. Genomics. 2018; 293 (3): 649-655. https://doi.org/10.1007/s00438-017-1408-z.

29. Kadushkin A.G., Taganovich A.D. [Role of chemokines in the pathogenesis of chronic obstructive pulmonary disease]. Meditsinskiy zhurnal. 2012; 2 (40): 139-144. Available at: https://www.bsmu.by/medicaljournal/410ae4b922cd5f290bed413a27c7078a (in Russian).

30. Feghali-Bostwick C.A., Gadgil A.S., Otterbein L.E. et al. Autoantibodies in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2008; 177 (2): 156-163. https://doi.org/10.1164/rccm.200701-014OC.

31. Jing H., Liu L., Zhou J., Yao H. Inhibition of C-X-C motif chemokine 10 (CXCL10) protects mice from cigarette smoke-induced chronic obstructive pulmonary disease. Med. Sci. Monit. 2018; 24: 5748-5753. https://doi.org/10.12659/MSM.909864.

32. Costa C., Rufino R., Traves S.L. et al. CXCR3 and CCR5 chemokines in induced sputum from patients with COPD. Chest. 2008; 133 (1): 26-33. https://doi.org/10.1378/chest.07-0393.

33. Saetta M., Mariani M., Panina-Bordignon P. et al. Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2002; 165 (10): 1404-1409. https://doi.org/10.1164/rccm.2107139.

34. Nie L., Xiang R., Zhou W. et al. Attenuation of acute lung inflammation induced by cigarette smoke in CXCR3 knockout mice. Respir. Res. 2008; 9 (1): 82. https://doi.org/10.1186/1465-9921-9-82.

35. Nie L., Liu Z.J., Zhou W.X. et al. Chemokine receptor CXCR3 is important for lung tissue damage and airway remodeling induced by short-term exposure to cigarette smoking in mice. Acta Pharmacol. Sin. 2010; 31 (4): 436-442. https://doi.org/10.1038/aps.2009.192.

36. Akers I.A., Parsons M., Hill M.R. et al. Mast cell tryptase stimulates human lung fibroblast proliferation via protease-activated receptor-2. Am. J. Physiol. Lung Cell. Mol. Physiol. 2000; 278 (1): L193-201. https://doi.org/10.1152/ajplung.2000.278.1.L193.

37. Hansbro P.M., Hamilton M.J., Fricker M. et al. Importance of mast cell Prss31/transmembrane tryptase/tryptase-γ in lung function and experimental chronic obstructive pulmonary disease and colitis. J. Biol. Chem. 2014; 289 (26): 18214-18227. https://doi.org/10.1074/jbc.M114.548594.